Trials
Search / Trial NCT06431282

Hyaluronic Acid Delivery: CO2 Laser Versus Thulium Laser Treatment

Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · May 26, 2024

Trial Information

Current as of February 19, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying two types of laser treatments—CO2 laser and thulium laser—to see how well they help deliver a substance called hyaluronic acid (HA) into the skin. HA is often used to improve skin quality, especially for aging skin, but the usual method of injecting it can cause bumps for a few days. By using lasers first, the researchers want to find out how the skin changes at the microscopic level after HA is applied, which could lead to better results and fewer side effects.

To participate in this trial, you need to be a healthy adult between the ages of 65 and 74, and both men and women are welcome. However, if you are pregnant, breastfeeding, or have any open wounds in the area being treated, you won't be able to join. If you decide to participate, you can expect to receive one of the laser treatments followed by the HA application, and the study aims to explore how these methods work together to improve skin quality. This could be an exciting opportunity to contribute to research that may benefit others with similar skin concerns in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • - healthy male and female patients
  • Exclusion Criteria:
  • pregnancy, breast feeding
  • open wounds at the area to be treated

About Universitätsklinikum Hamburg Eppendorf

Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.

Locations

Hamburg, , Germany

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0